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In chapter 1 an overview of the content of the thesis is given. In chapter 2 current data on
telomerase in gynecological tumours, especially cervical and ovarian tumours, are reviewed.
In more than 85% of  gynecological  mal ignant  tumours unique overexpression of  te lomerase
activity has been found, while benign tumours and normal t issues do not display or only weakly
express telomerase activity. In cervical t issue, frequency oÍ telomerase activity is related to
grade of  cerv ica l  in t raepi thel ia l  neoplas ia (ClN)/cerv ica l  cancer .  In  a l l  gynecological  tumours,
the human telomerase reverse transcriptase (hTERT), the catalytic protein component of
telomerase, is the important determinant for telomerase activity, as has also been observed in
other malignanciesll-13. Additionally, several applications of determination of telomerase activity
as a possib le d iagnost ic  tool  and var ious ways for  inh ib i t ion of  te lomerase are summarised.
T cell telomere length in HIV-1 infection: no evidence for increased CD4. T cell turnover
Analys is  of  te lomere length dur ing a cer ta in t ime per iod in  cel ls  wi th no or  weak te lomerase
activity may serve as a marker for cell turnover. In human immunodeficiency virus type-1 (HlV-
'1  )  in fect ion i t  has been suggested that  CD4" T cel l  ( the T helper  cel ls)  turnover  is  increased,
resul t ing in  exhaust ion of  CD4- T cel l  renewal  and decl ine in  CD4- T cel ls .  In  chapter  3,
telomere length is examined in T cells from HIV-1 infected patients. lt reveals that telomere
length decreases in CD8. T cells (the cytotoxic T cells), but is stable in CD4' T cells during the
course of HIV-1 infection. This is not explained by differential telomerase activity. These data
provide evidence that turnover in the course of HIV- 1 infection may be lncreased considerably
in CD8. T cel ls ,  but  not  in  CD4. T cel ls .  These resul ts  are compat ib le wi th CD4- T cel l  decl ine
in HIV-1 infection caused bv interference with cell renewal.
Sequential telomere length measurement in breast cancer patients receiving standard
or  h igh-dose chemotherapy and stem cel l  t ransplantat ion
High-dose chemotherapy and peripheral blood stem cell transplantation may accelerate
te lomere length loss in  hematoporet ic  s tem cel ls .  Data inc luding pre-  and post- t reatment
samples are lacking. Therefore, in chapter 4 leukocyte telomere length and telomerase activity
are studied in breast cancer patients, before and after standard- or high-dose chemotherapy.
Peripheral blood hematologic parameters are decreased at both t, and t, (t,: 6 to 8
weeks after completion of chemo- and radiotherapy, and tr: 6 months after completion of
chemo- and radiotherapy) compared to to (directly prior to start of chemotherapy) In the patients
treated with high-dose chemotherapy all parameters are decreased, while in the patients treated
with standard-dose chemotherapy leukocytes and platelets are decreased All parameters are
lower after high-dose than after standard-dose treatment at t,. Mean (change of) telomere
length do not differ between the groups. Telomerase activity is below detection l imit in all
samples.  Reinfused CD34- numbers (marker  for  hematopoiet ic  progeni tor  ce l ls) ,  but  not
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(p<0.05) ,  leukocytes (p<0.001) and p late lets  (p<0.01)  at  t , ,  CD34.numbers are not  re lated to
te lomere length change.
In conclusion, while following standard- and high-dose chemotherapy (in particular) the
per ipheral  b lood hematologic  values in i t ia l ly  are lower,  no change of  mean te lomere length
and/or telomerase activity is observed. Therefore, in this setting, 6 to 8 weeks after completion
of chemo- and radiotherapy no support for accelerated telomere loss in hematopoietic stem
cel ls  due to hematologic  pro l i ferat ive st ress is  found.
Telomerase activity as a biomarker for (pre)neoplastic cervical disease in scrapings and
frozen sections from patients with abnormal cervical smear
Telomerase activity is nowadays determined with the telomeric repeat amplif ication protocol
(TRAP) assay,  which is  a polymerase chain react ion (PCR) based assay" t ' .  Telomerase
activity is almost exclusively upregulated in cancerous tissues and not or weakly expressed in
normal t issue2l . Hence, detection of telomerase activity may serve as a possible diagnostic tool
in  the detect ion of  (pre)neoplast ic  d isease.  In  chapter  5,  the d iagnost ic  va lue of  semi-
quant i ta t ive te lomerase act iv i ty  assessment  in  cerv ica l  scrapings together  wi th human
papil lomavirus (HPV) typing for detection of preneoplastic (ClN) and neoplastic ervical esions
is examined Subsequently, telomerase activity in cervical scrapings and frozen specimens from
the same pat ients are compared.
Telomerase activity is detectable in assessable scrapings, however, sensitivity and
negative predictrve value of the TRAP assay for CIN ll/ l l l  and cancer lesions are 25o/o and 28oÀ,
respectively, while specificity for no CIN or CIN I is 89%. In representative frozen sections,
frequency of detectable telomerase activity is related to grade of CIN/cancer (p<0.0005).
Telomerase activity levels in paired scrapings and frozen sections appears to be only weakly
related; telomerase-positive s ctions with telomerase-negative scrapings and vice versa (only
in CIN l l l )  are observed.  In  oncogenic HPV-negat ive scrapings,  no te lomerase act iv i ty  is
detected, but in frozen sections, telomerase activity appears to be unrelated to presence of
specific HPV types
From these data it is concluded that telomerase activity is more frequent in higher grade
CIN/cancer. Telomerase activity assessment in cervical scrapings has a low sensitivity for CIN
ll/ l l l  and/or cervical cancer and does not appear to be useful for primary screening for cervical
cancer. However, increased telomerase activity in frozen CIN sections may be a possible
marker  of  progressive d isease.
Telomerase in (pre)neoplastic cervical disease
One of the observations in chapter S is ihat telomerase activity levels in cervical scrapings are
only weakly related to telomerase activity levels in frozen sections from the same cervical esion.
This frequent discrepancy may be due to heterogeneity of telomerase activity in (pre)malignant
cervical lesions. Studies using rn slÍu hybridisation techniques for the expression of the RNA
component of telomerase, hTR, have not only shown dysregulation of telomerase activity and
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hTR expression, but also impodant heterogeneity in hTR expression, especially in premalignant
lesions oÍ different tumour types"-". In chapter 6, upregulation of hTR expression in
(pre)malignant cervical esions as determined by tn sÍu hybridisation and reverse transcriptase
PCR (rt-PCR) and hTERT mRNA, the catalytic subunit of telomerase, expression studied with
rt-PCR are analysed. Moreover, application of in situ hybridisation allows the evaluation of
possible heterogeneity of hTR expression within the cervical esions.
hTR as determined by ín sítu hybridisation is related to grade of CIN/cervical cancer
(p<0 001). In general, hybridisation patterns for hTR expression are homogeneous throughout
the lesion. hTR expression, as determined by rt-PCR is detected in most of the cervical
specimens. hTERT mRNA is related to grade of CIN/cervical cancer (p<0.01). hTR expression,
as determined by in slÍu hybridisation and hTERT mRNA expression by rt-PCR are related to
telomerase activity levels (p<0 001, p<0.05, respectively) and presence of oncogenic types of
HPV (both p<0.05). hTR expression levels by rt-PCR shows a trend with telomerase activity
levels, but not with presence of oncogenic HPV.
These data show frequent upregulation of hTR and hTERT mRNA expression in CIN
lesions which appear to occur earlier than induction of telomerase activity. The fact that semi-
quantitative hTERT mRNA as well as hTR levels are related to telomerase activity levels
il lustrates that in (pre)malignant cervical esions upregulation of both telomerase components
are imoortant for functional telomerase.
Telomerase and clinicopathologic prognostic factors in cervical cancer
We have shor,vn in chapter 5 and 6 that telomerase activity, hTR and hTERT mRNA expression
levels are related to grade of CIN/cervical cancer. Therefore, these components may also be
related to clinicopathological features. Furthermore, others have already reported that higher
telomerase activity is l inked to a worse prognosis in leukemias, in breast cancer and in
meningiomas'u-to. Therefore, in chapter 7 the potential relation between telomerase activity, hTR
and/or hTERT mRNA with 'classic' cl inicopathologic prognostic factors and survival in patients
with cervical cancer is described. Analysis of prognostic factors and survival is l imited to early
stage patients, primarily treated with radical hysterectomy.
Telomerase activity is not detected in the normal cervices and present in 79o/o f cervical
cancers (p<0.001). hTR is detected in all normal cervices and cervical cancers. hTERT mRNA
isdetected in  1 of  8 normal  cerv ices,  whi le  80% of  cerv ica l  cancers are posi t ive (p<0 001).  In
contrast o semi-quantitative hTR expression levels, semi-quantitative hTERT mRNA levels are
related to telomerase activity levels (p<0 01). Semi-quantitative t lomerase activity levels are
related to differentiation grade (p<0.05), but not to stage and histotype. In the early stage
patients primarily treated with radical hysterectomy, semi-quantitative levels of telomerase
activity are not related to tumour volume, vascular invasion or presence of metastatic lymph
nodes. hTR as well as hTERT mRNA are not related to any clinicopathological factor. Tumour
volume, vascular invasion and presence of metastatic lymph nodes are related to (progression
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In conclusion, frequent upregulation of telomerase activity and hTERT mRNA is related
to cervical cancers. while hTR is also detected in normal cervices. Telomerase is not applicable
as a prognostic factor in early stage cervical cancer patients, primarily treated with radical
hysterectomy.
Telomerase in relation to expression of p53, c-Myc, estrogen receptor and progesterone
receptor in ovarian tumours
In chapter  8 te lomerase act iv i ty ,  hTR and hTERT mRNA. in  benign,  border l ine and mal ignant
ovarran tumours are evaluated in relation to the expression of p53, c-Myc, estrogen receptor
(ER) and progesterone receptor  (PR).  Fur thermore,  re lat rons wi th known c l in icopatholoqic
factors as wel l  as surv iva i  in  mal ignant  ovar ian tumours are assessed.
Telomerase activity and hTERT mRNA are more frequently observed in malignant
compared to border l ine and benign tumours (both p<0 001),  whereas hTR expression is
commonly detected in all types of tumours. Telomerase activity was correlated with hTERT
mRNA expression (p.0.05), but not wrth hTR expressron. lmmunohistochemical staining of p53
has been shown to be related to mutated p53"'. Expression of p53 and c-Myc are more
frequent ly  detected in  mal ignant  compared to border l ine and benign tumours (both p<0 001)
Telomerase activity is positively related to p53 and c-Myc expression (both p<0.001), negatively
re lated to PR expression (p<0 05) ,  but  not  to  ER expression.  In  the mal ignant  ovar ian tumours
telomerase activity and hTERT mRNA expression are not related to stage, differentiation grade
or residual disease. However, semi-quantitative hTR expression levels are related to stage
(p<0 05), but not to differentiation grade and residual disease. Stage, differentiation grade,
residual tumour after f irst laparotomy and presence of ascites are good prognostic factors for
(progression free) survival in this study. Telomerase is not related to (progression free) survival.
ln  conclus ion,  these data suggest  hat  p53 expression (e.g.  mutated p53) and c-Myc
expression may be important for (up)regulation of telomerase activitv.
DISCUSSION
In thts  thesis  evaluat ion of  te lomere length and te lomerase act iv i ty  has been used to enlarge
insight in the pathophysiological mechanisms of different human diseases, as well as to improve
predict ion of  the course of  (gynecological )  mal ignant  tumours.
Analysis of telomere length for replicative history
It has been shown that analysis of telomere length can be a good marker for replicative history
of  ce l ls .  Telomere length as a marker  for  ce l l  turnover  can onty be assessed in normal  ce l ls ,
which contain no or weak telomerase activity Nevertheless, it has to be taken into account that
telomere length is a homeostasis, determined by cell proliferation and telomerase activity.
Therefore, one should also determine the telomerase activity before drawrng any conclusions
on cel lu lar  ageing Through the fact  that  te lomere length is  shor tening wi th each cel l  d iv is ion
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and thus with age, with a large difference between individuals, it is recommended that telomere
length is determined during a certain time period. Together with the telomerase activity data
realistic onclusions can be drawn on the replicative history of the cells. Disadvantages of the
tradi t ional  method for  measur ing the te lomere length (Southern analys is)  are that  a large
number of  ce l ls  ( t '1  0u)  is  requi red and th is  technique does not  prov ide in format ion on the
telomere length of individual chromosomes. Fluorescence rn situ hybridisation2aa nd primed ln
slfu assay2a5 allow telomere length determination in individual chromosomes, while flow
cytometry method using fluorescence rn srïu hybridisation allows telomere length measurement
in indiv idual  ce l ls2a6.  These k ind of  assays may be helpfu l  in  s tudying which cel ls  and/or
chromosomes in premal ignant  t issues are beyond the cr i t ica l  te lomere length inducing cr is is .
Telomerase as diagnostic tool
Telomerase activity determination as a screening tool for cervical cancer in scrapings is not
applicable. For triage of patients with mildly abnormal cervical scrapings telomerase activity
determination seemed to be of modest clinical significance. However, the number of positive-
telomerase scrapings from patients with a mild or moderate dysplastic smear at referral was
smal l .
Apart from telomerase activity determination it may also be worthwhile to evaluate the
value of determination of hTR and/or hTERT mRNA levels in cervical scrapings. Due to rapid
degradation of telomerase proteins MUller ef a/.72 observed a very low sensitivity of the
telomerase activity assay for detection of bladder cancer in urine samples. Using a rt-PCR
assay for hTR, however, the sensitivity was increased to 85%. Rapid degradation of telomerase
proteins may also be a problem in cervical scrapings and therefore determination of hTR may
be more sensitive than examination of telomerase activity. However, t i l l  now no data exist on
hTR and/or hTERT mRNA in cervical scrapings.
Telomerase as marker for progressive disease
In several studies in other malignancies determination of telomerase activity has been
investigated for its possible use as biomarker for progressive disease. The natural history of
CIN is  uncer ta in,  but  progression has been presumed (and debated)  of  CIN l to  l l l  cu lminat ing
in invasive disease. The majority of low grade CIN lesions however wil l regress or remain
stable, with very few progressors. ln contrast, it is estimated that 35-75ok of high grade CIN lesi-
ons wil l progress to cancer over 20 yearsss. In general, presence and levels of telomerase
activity, hTR using rn situ hybridisation and hTERT mRNA expression are related to grade of
CIN/cancer and it is suggested that upregulation of telomerase may be an early event in cervical
carcinogenesis. Thus, it may be interesting to investigate whether or not CIN ll l  lesions positive
for telomerase are in a more progressive state than their negative counterparts. However, larger
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General discusslon 1 13
Telomerase as therapeutic target
Although the observation that telomerase can not be used as a prognostic factor in cervical,
ovarian and breast canceÉ16'217, we and others show that telomerase is strongly associated with
canceÉ'. Therefore, telomerase is an interesting target for therapeutic intervention. Numerous
preclinical studies have examined several ways for inhibit ion of telomerase through hTR-
antisense treatments, which resulted in telomeric attrit ion, and ultimately in cell deaths8s-s8221 .
However, issues on the use of anti-telomerase agents with regard to delivery, toxicity and
resis tance remain to be fur ther  s tudied in  cel l  l ines and animal  models.  Due to shor ter
telomeres, especially premalignant and early malignant cells are the most promising targets for
these therapies. However, recent observations that anti{elomerase treatment may induce
apoptosis and/or may modulate sensitivity of cancer cells for chemotherapeutic drugs without
relevant elomeric attrit ionses8 present upregulated telomerase activity in malignant cells as an
interesting target Íor a new anticancer therapy modality.
Another strategy for anticancer therapy may be the intervention in regulation of hTERT
transcription as we and others show almost exclusive upregulation of hTERT mRNA in
mal ignant  tumours l ' -13.  The promoter  of  hTERT compr ises b inding s i tes Íor  the t ranscr ipt ion
factor c-Myc and hormone response elements for ER and PR35-38. Intervention in inhibit ion of
telomerase activity in vitro can be accomplished by treatment of cells with antisense c-Myc23e
or with the anti-oestradiol tamoxifen2a2. However, no data exist on inhibit ion of telomerase
activity in vivo with this kind of treatment.
The high specificity of hTERT to malignant t issues potentially allows gene therapy with
a p lasmid conta in ing a suic ide gene,  e.g.  the herpes s implex v i rus gene thymidine k inase,  wi th
upstream the hTERT promoter Through this kind of gene therapy potentially only hTERT
expressing cel ls ,  e .g.  the (pre)mal ignant  ce l ls ,  wi l l  d ie,  whi le  the not  hTERT expressing cel ls ,
e.g. the normal cells, are not affected. Very preliminary results show that this gene therapy in
mice resulted in regression of the tumour, while normal t issues were not affected2aT.
Whether or not this type of strategies wil l be successful for anticancer therapy in human
has to be further elucidated.
